Dr. Jeroen Buijs is a senior researcher at the Einthoven Laboratory for Vascular and Regenerative Medicine at the Div. Thrombosis and Hemostasis (Dept. Internal Medicine, LUMC). Dr. Buijs has an H-factor of 22, and co-authored 39 peer-reviewed publications (of which 18 first/senior author), which have been cited more than 2000x. He serves the Editorial Boards of Cancers (2020 – current) and BioMed Research International - Oncology (2012-2020), the Reviewer Board of Cancers (2019 - ), and has acted as reviewer and chairman at the conference of the Dutch Thrombosis Society (NVTH). The focus of Jeroen Buijs’ research is to better understand the interactions between cancer and thrombosis: 1. Development of new cancer and thrombosis in vivo models to study the effects of cancer on thrombosis, and vice versa, the effects of (anti-)coagulation on cancer progression. 2. Identification of novel plasma biomarkers using a mass spectrometry-based targeted proteomics approach to better select patients at high risk for cancer-associated thrombosis for thromboprophylaxis. 3. Discovery of cancer-associated thrombosis (CAT) gene signatures in glioblastoma, pancreatic cancer, osteosarcoma and colorectal cancer, using next generation mRNA and microRNA sequencing, and targeted DNA sequencing. 4. Subsequent validation of CAT-gene signatures by genetic modification of tumor cells and testing in in vitro coagulation assay and cancer & thrombosis preclinical models.